Kicking off 2024 with five new R&D partnerships
We are kicking off 2024 with five new R&D partnerships to further enable and accelerate the company’s commitment to transform the lives of patients world-wide.
Search
Obesity
Obesity
Generalized pustular psoriasis (GPP): a chronic inflammatory disease
Learn more about this chronic inflammatory disease associated with skin and systemic symptoms
Survodutide US FDA Breakthrough Therapy phase 3 trials MASH
Boehringer receives U.S. FDA Breakthrough Therapy designation and initiates two phase III trials in MASH for survodutide
Partnering in Central Nervous System Diseases
We are looking for new early-science collaborations. Join our expanding community of innovation partners in central nervous system diseases.
Life forward - Boehringer Ingelheim company brand
Life forward - Boehringer Ingelheim unveils its evolved company brand
FDA accepts new chronic kidney disease treatment application
FDA accepts new chronic kidney disease treatment application
Advancing health: Our impactful R&D investments
Discover how we’re investing in sustainable impact with an unwavering commitment to research and development
Scleroderma
Systemic sclerosis is a complex rare disease with a variable course. It presents with a range of symptoms involving several different organs
Dan
People with Type 2 diabetes (T2D) have an increased risk of heart disease
Boehringer partners with NCD Alliance
Boehringer Ingelheim partners with NCD Alliance to target Non-Communicable Diseases in underserved communities
A Unique Bond: there’s nothing like it
It's not easy to live with systemic sclerosis, but the remarkable relationship Anna has built with Csenge has helped her realise her capabilities.
Results for Jardiance EMPACT-MI phase III trial
Results announced from EMPACT-MI phase III trial investigating the effect of Jardiance® (empagliflozin) on risk of heart failure hospitalization and death in adults following a heart attack
Liu
Hear Liu share his experience of being diagnosed with type 2 diabetes and heart disease on the same day and the impact this simultaneous diagnosis has had on his life as he knew it.
Professor Baumgart
Information for people with type 2 diabetes (T2D) on why it is important to consider their heart and suggested measures that can be taken to reduce the risk of heart disease
Elke
People with Type 2 diabetes (T2D) have an increased risk of heart disease.
Isabel
In this video, Isabel shares how watching her children and grandchildren grow up inspires her to take the necessary steps to manage her life with type 2 diabetes and heart disease.
Reinhold
People with type 2 diabetes have an increased risk of heart disease and this can have a profound impact on their everyday lives
FDA approves Jardiance treatment chronic kidney disease
U.S. FDA approves Jardiance® for treatment of adults with chronic kidney disease
Patient documentary - From diagnosis to everyday living
EU approved Jardiance for type 2 diabetes in children
Jardiance® (empagliflozin) receives approval in the EU for the treatment of type 2 diabetes in children aged 10 years and above
Transforming Science Day
How our ‘patient first’ approach to innovation is aiming to accelerate breakthrough therapies that transform lives. Join our Transforming Science Day.
Phase II clinical trial weight loss results
Data shows nearly 19% weight loss in people with overweight or obesity in Phase II trial with survodutide (BI 456906)
Technologies
We are expanding our global network of technology partners Learn more about partnering with us.
Translational Medicine & Clinical Pharmacology
We connect the right patient with the right drug on the right dosing schedule using data science methods from pharmacometrics to systems pharmacology.